Cagrilintide
$50.99
Cagrilintide (AM833) is a long-acting synthetic analog of amylin studied for its activity at amylin and calcitonin receptors. It has been evaluated in clinical research related to metabolic and endocrine signaling pathways involved in appetite regulation, energy balance, and glucose control mechanisms.
Usage Disclaimer: Research Use Only. This product is intended strictly for laboratory research and in-vitro studies. It is not for human or animal consumption, medical use, or diagnostic purposes. Any unauthorized use of this product is strictly prohibited.
FDA Compliance: FDA Notice. The statements made regarding these products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Research Studies
REDEFINE 1 Trial - Phase 3 Weight Loss (2025)
Humans | 2.4 mg weekly | 68 weeks | 22.7% weight loss vs 2.4% placebo
Landmark Phase 3 trial published in NEJM demonstrating superior weight loss with CagriSema combination in 3,417 adults with obesity, achieving primary endpoints with excellent safety profile.
REDEFINE 2 Trial - Phase 3 Type 2 Diabetes (2025)
Humans | 2.4 mg weekly | 68 weeks | 15.7% weight loss, 73.5% achieved HbA1c ≤6.5%
Phase 3 trial in 1,206 adults with type 2 diabetes and obesity published in NEJM, demonstrating significant weight loss and glycemic improvements with CagriSema.
Thorough QT Study - Cardiac Safety (2024)
Humans | 4.5 mg single dose | 5 days | No clinically relevant QTc prolongation
Dedicated cardiac safety study confirming no significant QT interval prolongation at supratherapeutic doses, supporting cardiovascular safety profile.
Pair your peptide order with bacteriostatic water for proper reconstitution and storage. Adding it now ensures you have everything you need when your order arrives.
Avoid delays and complete your setup in one shipment.
